Multi-pronged approaches to reducing the health consequences of opioid use, New York City


Northeast Epidemiology Conference

What is the strategy?

- Public health approach
 - Track drug use and associated health consequences at a population level
- Comprehensive and timely surveillance
- Develop data-driven initiatives
- · Impact is measureable

Public health surveillance framework

- Prevalence who, what, where
- · Morbidity who, what, where
- Mortality- who, what, where
- Qualitative how and why



PRESCRIPTION MONITORING PROGRAM


PMP for public health surveillance


- To understand population level
 prescription use trends over time
 - Historically, used as law enforcement tool
 - NYC DOHMH developed key indicators to evaluate data using the PMP
- · To inform data-driven initiatives

Key public health PMP indicators


- Number of prescriptions, patients, prescriber, pharmacies
- Rate of opioid analgesic prescriptions filled overall and by drug type
- · Median day supply
- Rate of patients filling opioid analgesic prescriptions
- Rate of high dose opioid analgesic prescriptions filled


Rate of opioid analgesic prescriptions filled by borough of residence, 2013















Timely mortality data

- NYC receives mortality data monthly and reports data quarterly
- Prior to 2013 data was received annually and reported with a 1.5 year lag
- NYC published preliminary 2013 mortality data in July 2014
 - Time lag for the CDC is currently > 1 year










4

Syndromic surveillance

- · An early warning system
- NYC receives data daily from 51 emergency department
- Emergency department visits are classified into "syndromes" based on chief complaint
- Syndromes are compared to baseline data to identify changing trends



Timely nature of syndromic data used to guide public health responses

- Rapid assessment
 - Can include chart review, qualitative interviews, short surveys
- · Rapid response
 - Engaging community stakeholders, strategic naloxone deployment, development of educational materials, etc.

CASE STUDY: DATA DRIVEN INITIATIVES

Fentanyl and heroin-involved overdoses

- 2014: Mid-Atlantic and Northeast states reported an increase in the number of overdoses related to heroin containing fentanyl
- February, 2014: Mass media coverage of heroin following the death of a public figure in New York City
 - Concern that fentanyl-involved overdose deaths would increase in NYC

What would you do?

Multi-agency response

- NYC Department of Health and Mental Hygiene (DOHMH) developed list of questions for existing datasets
- Multi-agency conference calls led by DOHMH
 - Medical examiner, NYPD, DEA, Manhattan DA office, NY/NJ HIDTA, Special Narcotics Prosecutor, Mayor's Office

Investigation findings

- · Public health
 - Medical Examiner
 - No increase in the number of overdose cases
 - Retrospectively tested all heroin deaths for fentanyl for the month of January
 - Syndromic surveillance
 - No detectable increase in the number of emergency department visits for overdose
- Poison Control data
 - No increase in the number of consultations for heroin or fentanyl

Investigation findings

- Public safety
 - NYPD and DEA labs
 - No reported increase heroin samples tested containing fentanyl
- Community
 - Syringe Exchange Programs
 - No reported increase in fatal or non fatal overdoses


Data-driven response


- NYC DOHMH released two advisories regarding cases of fentanyl-associated overdoses in Mid-Atlantic and Northeast United States (2014)
 - A Health Alert Network letter for clinicians
 - A "Dear Colleague" letter for community program staff working with drug users
- Continued public health and public safety surveillance


Public safety response

- Included aggressive investigation of decedent's dealer and subsequent arrest
- Discussed importance of routinely testing product and sharing results, including purity


How have others responded to similar events?










8









9


Judicious Opioid Prescribing Public Health Detailing Campaign

- Modeled after pharmaceutical sales approach
- · Effective in changing clinical practice behavior
- "Sell" or promote key recommendations focusing on safe and judicious prescribing
- 8 week campaign (Spring 2015); 2 visits per contact
- · Brief, 1:1 interactions with providers and staff
- Provide key messages, clinical tools, patient materials
- Evaluation: knowledge assessment at beginning of 1st and 2nd visit

Seven steps of a detailing visit

- 1. Introductions
- 2. Framing the issue
- 3. Survey questions
- 4. Stating recommendations
- 5. Promoting materials in kit
- 6. Handling objections
- 7. Gaining a commitment

Key campaign messages



When opioids are warranted, a three-day supply is usually sufficient.

- Avoid prescribing opioids to patients taking benzodiazepines whenever possible.
- Use ≥100 MME as a threshold for caution and thorough patient reassessment.

Action kit highlights

Provider information

- · National and local data about opioid analgesic epidemic
- Prescribing guidelines
- OpioidCalc
- New York State Prescription Monitoring Program
- Substance use disorder treatment referral

Naloxone

Patient information

- Posters
- Brochures







Evaluation of health care provider knowledge

- 3-question survey
 - Self-reported knowledge related to campaign recommendations
- Reps administered survey to health care providers at beginning of initial and followup visits
- Very brief, ~2 minutes

Detailing visit process data

- Health care provider visits
 - 972 initial visits
 - 814 follow-up visits (84% follow-up rate)
- Non-health care provider office staff – 504 initial visits
 - 341 follow-up visits

Detailing campaign increased prescriber knowledge

Recommendation	Initial Visit % Correct (n/N)	Follow-up Visit % Correct (n/N)
3-day supply for acute pain	50% (484/972)	75% (611/814)
Concern co- prescribing with benzodiazepines	94% (910/972)	97% (789/814)
100 MME = DOHMH threshold for reassessment	9% (90/972)	62% (503/814)

Conclusions

- Public health detailing campaign reached nearly 1000 Bronx health care providers in specialties that prescribe the most OAs
- · Campaign well-received
- Campaign changed health care provider knowledge about opioid prescribing
- Other jurisdictions might consider public health detailing on opioid analgesics

Buprenorphine: A Clinical and Public Health Strategy to Prevent Opioid Overdose

Jessica Kattan, MD, MPH 10/1/15

Overview of medication-assisted treatment for opioid use disorder (addiction)

- Medications are the most effective treatment for opioid use disorder
- · Gold standard medications:
 - Methadone
 - Can only be prescribed in addiction settings
 - Buprenorphine
 - Can be prescribed by general physicians or specialists in office-based setting

How does buprenorphine work?

· Partial opioid agonist

- Attaches to same receptors in the brain as other opioids (e.g., opioid analgesics, heroin, methadone), blocking their effects and preventing withdrawal symptoms
- Ceiling to side effects, including respiratory depression
- Produces only weak morphine-like effects, without the high triggered by full opioid agonists
- Long-acting and blocks the effects of any opioids taken after its administration
- Available in tablet or film formulation

Effectiveness

- Demonstrated in multiple studies to be effective treatment for opioid use disorder
- Reduces
 - Opioid use
 - Mortality
- May also reduce risk of HIV infection

How long should a person take buprenorphine?

- Every person is different → depends on individual
- Better outcomes with longer treatment
- · Diabetes treatment analogy

What about misuse and diversion of buprenorphine?

- Risk of misuse is lower with buprenorphine than with full opioid agonists
 - Not drug of choice to get high
 - Long-acting with ceiling effect \rightarrow limits euphoria
 - Naloxone included in Suboxone formulation to deter injection $\ensuremath{\mathbb{R}}$
- Most common reasons for buprenorphine misuse:
 - Self-treatment of withdrawal symptoms
 - Lack of access to treatment

Barriers to access/utilization

- · Prescribing restrictions
 - Only MDs and DO
 - 8-hour training
 - Limits on number of patients
- · Lack of physician familiarity
- Lack of physician time to manage and coordinate care
- · Prior authorizations
- Stigma

Health Department strategy to increase access

- Programs to increase local prescribing capacity
 - Provide technical assistance to health centers
 - RFP for nurse care manager model
- Work with other governmental agencies on policy development
- Materials for health care providers and patients
- · Messaging to decrease stigma

Buprenorphine CHI Image: City Health Information Values 24 (2015) Texes Very Department of Health and Mental Hygens Murrenorphine treatment is a life-saving tool for patients with opioid use disorder. Duprenorphine treatment is a life-saving tool for patients with opioid use disorder. • Buprenorphine treatment is a life-saving tool for patients with opioid use disorder. • Learn to recognize opioid use disorder and recommend effective treatment. • Incorporate buprenorphine treatment into your practice. • Market and the source operation of the saving tool for patients with opioid use disorder.

Summary

- Buprenorphine is a key NYC DOHMH strategy to reduce risk of opioid overdose
- Buprenorphine is effective – Reduces opioid use and mortality
- Buprenorphine is safe
 Ceiling effect→ difficult to overdose
- Can be prescribed by physicians in office-based settings
- Barriers exist
- NYC DOHMH is actively working to increase access
- Other jurisdictions should include expanding access to buprenorphine as a strategy to reduce opioid overdose

DISCUSSION